Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients

Dario Cattaneo, Cristina Gervasoni, Valeria Cozzi, Sara Baldelli, Serena Fucile, Paola Meraviglia, Simona Landonio, Gabriella Boreggio, Giuliano Rizzardini, Emilio Clementi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The potential drug-to-drug interaction between darunavir and raltegravir in the setting of HIV infection is a highly debated issue still unresolved. In the present study we have evaluated the pharmacokinetics of darunavir and ritonavir in 53 HIV-1 infected patients with or without concomitant raltegravir administration. The assessment of trough plasma drug concentrations was carried out in all subjects and the potential influence of raltegravir on darunavir and ritonavir disposition, assessed by specific pharmacokinetic evaluations in a subgroup of 25 patients. No significant differences on darunavir and ritonavir plasma trough levels were observed between patients receiving or not raltegravir. Co-administration of raltegravir was, however, associated with a 40% reduction in darunavir C max and estimated AUC 0-24, as well a 60% increase in the estimated darunavir clearance compared with values measured in patients not given raltegravir. Notably, this interaction was independent of the dosage of darunavir and not due to effects of raltegravir on the pharmacokinetics of ritonavir. These results should be taken into account when darunavir-based regimens are implemented in the setting of HIV, especially considering that this drug is usually administered at fixed daily dose and no therapeutic drug monitoring is performed in most centres.

Original languageEnglish
Pages (from-to)198-203
Number of pages6
JournalPharmacological Research
Volume65
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

HIV-1
Ritonavir
Pharmacokinetics
Pharmaceutical Preparations
Raltegravir Potassium
Darunavir
Drug Monitoring
Drug Interactions
Area Under Curve
HIV Infections
HIV

Keywords

  • Darunavir
  • Drug-to-drug interactions
  • HIV
  • Pharmacokinetics
  • Raltegravir
  • Ritonavir

ASJC Scopus subject areas

  • Pharmacology

Cite this

Cattaneo, D., Gervasoni, C., Cozzi, V., Baldelli, S., Fucile, S., Meraviglia, P., ... Clementi, E. (2012). Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients. Pharmacological Research, 65(2), 198-203. https://doi.org/10.1016/j.phrs.2011.09.006

Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients. / Cattaneo, Dario; Gervasoni, Cristina; Cozzi, Valeria; Baldelli, Sara; Fucile, Serena; Meraviglia, Paola; Landonio, Simona; Boreggio, Gabriella; Rizzardini, Giuliano; Clementi, Emilio.

In: Pharmacological Research, Vol. 65, No. 2, 02.2012, p. 198-203.

Research output: Contribution to journalArticle

Cattaneo, D, Gervasoni, C, Cozzi, V, Baldelli, S, Fucile, S, Meraviglia, P, Landonio, S, Boreggio, G, Rizzardini, G & Clementi, E 2012, 'Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients', Pharmacological Research, vol. 65, no. 2, pp. 198-203. https://doi.org/10.1016/j.phrs.2011.09.006
Cattaneo, Dario ; Gervasoni, Cristina ; Cozzi, Valeria ; Baldelli, Sara ; Fucile, Serena ; Meraviglia, Paola ; Landonio, Simona ; Boreggio, Gabriella ; Rizzardini, Giuliano ; Clementi, Emilio. / Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients. In: Pharmacological Research. 2012 ; Vol. 65, No. 2. pp. 198-203.
@article{241ff51e723246d0a017fadb72100cd0,
title = "Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients",
abstract = "The potential drug-to-drug interaction between darunavir and raltegravir in the setting of HIV infection is a highly debated issue still unresolved. In the present study we have evaluated the pharmacokinetics of darunavir and ritonavir in 53 HIV-1 infected patients with or without concomitant raltegravir administration. The assessment of trough plasma drug concentrations was carried out in all subjects and the potential influence of raltegravir on darunavir and ritonavir disposition, assessed by specific pharmacokinetic evaluations in a subgroup of 25 patients. No significant differences on darunavir and ritonavir plasma trough levels were observed between patients receiving or not raltegravir. Co-administration of raltegravir was, however, associated with a 40{\%} reduction in darunavir C max and estimated AUC 0-24, as well a 60{\%} increase in the estimated darunavir clearance compared with values measured in patients not given raltegravir. Notably, this interaction was independent of the dosage of darunavir and not due to effects of raltegravir on the pharmacokinetics of ritonavir. These results should be taken into account when darunavir-based regimens are implemented in the setting of HIV, especially considering that this drug is usually administered at fixed daily dose and no therapeutic drug monitoring is performed in most centres.",
keywords = "Darunavir, Drug-to-drug interactions, HIV, Pharmacokinetics, Raltegravir, Ritonavir",
author = "Dario Cattaneo and Cristina Gervasoni and Valeria Cozzi and Sara Baldelli and Serena Fucile and Paola Meraviglia and Simona Landonio and Gabriella Boreggio and Giuliano Rizzardini and Emilio Clementi",
year = "2012",
month = "2",
doi = "10.1016/j.phrs.2011.09.006",
language = "English",
volume = "65",
pages = "198--203",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "2",

}

TY - JOUR

T1 - Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients

AU - Cattaneo, Dario

AU - Gervasoni, Cristina

AU - Cozzi, Valeria

AU - Baldelli, Sara

AU - Fucile, Serena

AU - Meraviglia, Paola

AU - Landonio, Simona

AU - Boreggio, Gabriella

AU - Rizzardini, Giuliano

AU - Clementi, Emilio

PY - 2012/2

Y1 - 2012/2

N2 - The potential drug-to-drug interaction between darunavir and raltegravir in the setting of HIV infection is a highly debated issue still unresolved. In the present study we have evaluated the pharmacokinetics of darunavir and ritonavir in 53 HIV-1 infected patients with or without concomitant raltegravir administration. The assessment of trough plasma drug concentrations was carried out in all subjects and the potential influence of raltegravir on darunavir and ritonavir disposition, assessed by specific pharmacokinetic evaluations in a subgroup of 25 patients. No significant differences on darunavir and ritonavir plasma trough levels were observed between patients receiving or not raltegravir. Co-administration of raltegravir was, however, associated with a 40% reduction in darunavir C max and estimated AUC 0-24, as well a 60% increase in the estimated darunavir clearance compared with values measured in patients not given raltegravir. Notably, this interaction was independent of the dosage of darunavir and not due to effects of raltegravir on the pharmacokinetics of ritonavir. These results should be taken into account when darunavir-based regimens are implemented in the setting of HIV, especially considering that this drug is usually administered at fixed daily dose and no therapeutic drug monitoring is performed in most centres.

AB - The potential drug-to-drug interaction between darunavir and raltegravir in the setting of HIV infection is a highly debated issue still unresolved. In the present study we have evaluated the pharmacokinetics of darunavir and ritonavir in 53 HIV-1 infected patients with or without concomitant raltegravir administration. The assessment of trough plasma drug concentrations was carried out in all subjects and the potential influence of raltegravir on darunavir and ritonavir disposition, assessed by specific pharmacokinetic evaluations in a subgroup of 25 patients. No significant differences on darunavir and ritonavir plasma trough levels were observed between patients receiving or not raltegravir. Co-administration of raltegravir was, however, associated with a 40% reduction in darunavir C max and estimated AUC 0-24, as well a 60% increase in the estimated darunavir clearance compared with values measured in patients not given raltegravir. Notably, this interaction was independent of the dosage of darunavir and not due to effects of raltegravir on the pharmacokinetics of ritonavir. These results should be taken into account when darunavir-based regimens are implemented in the setting of HIV, especially considering that this drug is usually administered at fixed daily dose and no therapeutic drug monitoring is performed in most centres.

KW - Darunavir

KW - Drug-to-drug interactions

KW - HIV

KW - Pharmacokinetics

KW - Raltegravir

KW - Ritonavir

UR - http://www.scopus.com/inward/record.url?scp=84856018356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856018356&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2011.09.006

DO - 10.1016/j.phrs.2011.09.006

M3 - Article

C2 - 21958880

AN - SCOPUS:84856018356

VL - 65

SP - 198

EP - 203

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 2

ER -